OnKure Therapeutics, Inc. - OKUR
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 27, 2026 | SCHEDULE 13G | BIOTECHNOLOGY VALUE FUND L P | 2.7% | 1,095,373 | View |
| May 27, 2026 | SCHEDULE 13G | BVF I GP LLC | 2.7% | 1,095,373 | View |
| May 27, 2026 | SCHEDULE 13G | BIOTECHNOLOGY VALUE FUND II LP | 2.1% | 854,705 | View |
| May 27, 2026 | SCHEDULE 13G | BVF II GP LLC | 2.1% | 854,705 | View |
| May 27, 2026 | SCHEDULE 13G | Biotechnology Value Trading Fund OS LP | 0.4% | 153,595 | View |
| May 27, 2026 | SCHEDULE 13G | BVF Partners OS Ltd. | 0.4% | 153,595 | View |
| May 27, 2026 | SCHEDULE 13G | BVF GP HOLDINGS LLC | 4.8% | 1,950,078 | View |
| May 27, 2026 | SCHEDULE 13G | BVF PARTNERS L P/IL | 5.3% | 2,134,908 | View |
| May 27, 2026 | SCHEDULE 13G | BVF INC/IL | 5.3% | 2,134,908 | View |
| May 27, 2026 | SCHEDULE 13G | LAMPERT MARK N | 5.3% | 2,134,908 | View |
| May 15, 2026 | SCHEDULE 13G/A | ADAR1 Capital Management, LLC | 6.0% | 2,434,941 | View |
| May 15, 2026 | SCHEDULE 13G/A | ADAR1 Capital Management GP, LLC | 5.0% | 2,038,429 | View |
| May 15, 2026 | SCHEDULE 13G/A | Daniel Schneeberger | 6.0% | 2,434,941 | View |
| Apr 07, 2026 | SCHEDULE 13D | — | 19.99% | 3,998,332 | View |
| Apr 07, 2026 | SCHEDULE 13G | StepStone Group LP | 6.6% | 2,660,612 | View |
| Apr 07, 2026 | SCHEDULE 13G | StepStone Master G, L.P. | 6.6% | 2,660,612 | View |
| Apr 07, 2026 | SCHEDULE 13G | StepStone VC MI-G GP, LLC | 6.6% | 2,660,612 | View |
| Apr 07, 2026 | SCHEDULE 13G | Trails Edge Capital Partners, LP | 6.0% | 2,409,638 | View |
| Apr 07, 2026 | SCHEDULE 13G | Trails Edge Biotechnology Master Fund, LP | 6.0% | 2,409,638 | View |
| Apr 07, 2026 | SCHEDULE 13G | Ortav Yehudai | 6.0% | 2,409,638 | View |
| Apr 07, 2026 | SCHEDULE 13G | RA Capital Management, L.P. | 9.9% | 4,038,715 | View |
| Apr 07, 2026 | SCHEDULE 13G | Peter Kolchinsky | 9.9% | 4,038,715 | View |
| Apr 07, 2026 | SCHEDULE 13G | Rajeev Shah | 9.9% | 4,038,715 | View |
| Apr 07, 2026 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 9.9% | 4,038,715 | View |
| Apr 01, 2026 | SCHEDULE 13G | ACORN BIOVENTURES, L.P. | 4.5% | 1,854,525 | View |
| Apr 01, 2026 | SCHEDULE 13G | ACORN CAPITAL ADVISORS GP, LLC | 4.5% | 1,854,525 | View |
| Apr 01, 2026 | SCHEDULE 13G | ACORN BIOVENTURES 2, L.P. | 5.0% | 2,069,512 | View |
| Apr 01, 2026 | SCHEDULE 13G | Acorn Capital Advisors GP 2, LLC | 5.0% | 2,069,512 | View |
| Apr 01, 2026 | SCHEDULE 13G | Anders Hove | 9.5% | 3,924,037 | View |
| Feb 17, 2026 | SCHEDULE 13G | ADAR1 Capital Management, LLC | 7.9% | 1,014,158 | View |
| Feb 17, 2026 | SCHEDULE 13G | ADAR1 Capital Management GP, LLC | 6.2% | 793,602 | View |
| Feb 17, 2026 | SCHEDULE 13G | Daniel Schneeberger | 7.9% | 1,014,158 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Highbridge Capital Management, LLC | 4.2% | 542,361 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Advisors LLC | 0.4% | 48,957 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Advisors Holdings LP | 0.4% | 48,957 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel GP LLC | 0.4% | 48,957 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Securities LLC | 1.4% | 174,168 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Securities Group LP | 1.4% | 174,168 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Securities GP LLC | 1.4% | 174,168 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kenneth Griffin | 1.7% | 223,125 | View |
| Jan 30, 2026 | SCHEDULE 13G/A | The Vanguard Group | 4.87% | 626,593 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.